# TRACON Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tracon-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.traconpharma.com
- Total disclosed funding: $41M
- Latest round: Series B (Sep 22, 2014)
- Investors on record: 8

## About

TRACON Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer and serious diseases, utilizing targeted biologics to improve treatment outcomes for patients.TRACON Pharmaceuticals Inc. specializes in developing therapies for oncology, founded in 2006 and headquartered in San Diego, US. The company raised USD 36 mn in an IPO in January 2015 and subsequently sold shares in November 2016 for USD 15.09 mn and in August 2020 for USD 5.08 mn. Their most recent funding round was Venture Debt, raising USD 10.00 mn from Runway Growth Capital, bringing the total amount raised to USD 5.00 mn.TRACON Pharmaceuticals, Inc. is engaged in developing and commercializing innovative cancer therapies through targeted biologics designed to selectively target cancerous cells. Their product offerings include investigational therapeutics aimed at addressing unmet medical needs in oncology, focusing on specific genetic markers or tumor types. The company markets its products in the United States and selected international markets, catering to healthcare providers and patients undergoing cancer treatments.In 2023, TRACON Pharmaceuticals, Inc. generated revenue of USD 12.04 mn with an EBITDA of USD -1.93 mn, reflecting their ongoing partnerships and collaborations in the biopharmaceutical sector, structured around licensing agreements and research funding.TRACON Pharmaceuticals plans to advance its pipeline of targeted therapies, with specific product launches aimed at addressing additional oncology indications expected in the coming years. The company is also focused on expanding its market presence into Europe and Asia by 2025, aiming to reach new patient populations. The recent funding of USD 10.00 mn will support these initiatives as they look to strengthen their product development and market access strategies.

## Funding rounds

- Series B, Sep 22, 2014, $27M — New Enterprise Associates, Nextech, Arcus Ventures, Brookline Venture Partners, BioMed Ventures
- Series A, Mar 31, 2011, $14M — Icon Ventures, Nextech, Arcus Ventures, Brookline Partners, BHP

## Investors

- Icon Ventures (https://capitalatlas.ai/funds/icon-ventures) — Series A
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B
- Arcus Ventures (https://capitalatlas.ai/funds/arcus-ventures) — Series A, Series B
- Brookline Partners — Series A
- BHP (https://capitalatlas.ai/funds/bhp) — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- Brookline Venture Partners (https://capitalatlas.ai/funds/brookline-venture-partners) — Series B
- BioMed Ventures — Series B